S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Forecast, Price & News

$4.18
+0.03 (+0.72%)
(As of 09/22/2023 08:52 PM ET)
Compare
Today's Range
$4.08
$4.30
50-Day Range
$4.15
$11.99
52-Week Range
$4.08
$16.48
Volume
229,300 shs
Average Volume
335,579 shs
Market Capitalization
$184.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50

Stoke Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
462.2% Upside
$23.50 Price Target
Short Interest
Bearish
15.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.72mentions of Stoke Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$159,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.58) to ($2.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

294th out of 963 stocks

Pharmaceutical Preparations Industry

121st out of 452 stocks


STOK stock logo

About Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.

STOK Price History

STOK Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Stoke Therapeutics Is Unable To Derisk Its Platform
Stoke Therapeutics (STOK) Receives a Buy from BTIG
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Why Shares of Stoke Therapeutics Plummeted Tuesday
The Latest Analyst Ratings for Stoke Therapeutics
Why Stoke Therapeutics Is Trading Lower Today?
What 8 Analyst Ratings Have To Say About Stoke Therapeutics
See More Headlines
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Company Calendar

Last Earnings
8/07/2023
Today
9/24/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
117
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.50
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+462.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-101,070,000.00
Net Margins
-679.83%
Pretax Margin
-1,186.72%

Debt

Sales & Book Value

Annual Sales
$12.40 million
Book Value
$4.69 per share

Miscellaneous

Free Float
38,636,000
Market Cap
$185.01 million
Optionable
Not Optionable
Beta
0.35
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Edward M. Kaye M.D.Dr. Edward M. Kaye M.D. (Age 74)
    Ph.D., CEO & Director
    Comp: $931.21k
  • Dr. Adrian R. Krainer Ph.D. (Age 64)
    Co-Founder & Independent Director
    Comp: $44k
  • Mr. Stephen J. Tulipano CPA (Age 64)
    CPA, MBA, Chief Financial Officer
    Comp: $619.09k
  • Dr. Barry S. Ticho FACC (Age 62)
    M.D., Ph.D., Chief Medical Officer
    Comp: $688.83k
  • Ms. Isabel Aznarez Ph.D. (Age 50)
    Co-Founder & Group VP of Discovery Research
  • Dr. Huw M. Nash Ph.D. (Age 56)
    COO & Chief Bus. Officer
  • Mr. Eric Rojas
    Head of Investor Relations
  • Mr. Jonathan Allan J.D. (Age 33)
    Corp. Sec. & Gen. Counsel
  • Ms. Dawn Kalmar (Age 45)
    Chief Communications Officer
  • Ms. Joan Wood
    Chief HR Officer













STOK Stock - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STOK shares.
View STOK analyst ratings
or view top-rated stocks.

What is Stoke Therapeutics' stock price forecast for 2023?

9 brokerages have issued 1-year price objectives for Stoke Therapeutics' stock. Their STOK share price forecasts range from $12.00 to $35.00. On average, they expect the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 462.2% from the stock's current price.
View analysts price targets for STOK
or view top-rated stocks among Wall Street analysts.

How have STOK shares performed in 2023?

Stoke Therapeutics' stock was trading at $9.23 at the beginning of 2023. Since then, STOK stock has decreased by 54.7% and is now trading at $4.18.
View the best growth stocks for 2023 here
.

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our STOK earnings forecast
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06. The company earned ($2.48) million during the quarter, compared to analysts' expectations of $4 million. Stoke Therapeutics had a negative net margin of 679.83% and a negative trailing twelve-month return on equity of 52.94%.

What ETFs hold Stoke Therapeutics' stock?

ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and Simplify Propel Opportunities ETF (SURI).Global X Genomics & Biotechnology ETF (GNOM).

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cowen AND Company LLC (8.42%), BlackRock Inc. (5.18%), Geode Capital Management LLC (1.36%), State Street Corp (1.25%), Granahan Investment Management LLC (1.20%) and M28 Capital Management LP (0.78%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Jonathan Allan and Stephen J Tulipano.
View institutional ownership trends
.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $4.18.

How much money does Stoke Therapeutics make?

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $185.01 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

The company employs 117 workers across the globe.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.

This page (NASDAQ:STOK) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -